Physician profile
Peter T Gardner
NPI 1821127093
$2,752.03
in general payments reported to CMS, 2019-2025
28 companies · $21.88 in 2025
The $21.88 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $459 · 2021: $594 · 2022: $437 · 2023: $407 · 2024: $406 · 2025: $21.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $677.13 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Genentech USA, INC. | $342.47 | 2019-2020 | |
| Abbvie INC. | $291.95 | 2021-2024 | |
| Lilly USA, LLC | $244.83 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $233.93 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $177.81 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $173.05 | 2022-2024 | |
| Allergan, INC. | $165.28 | 2019-2020 | |
| Pfizer INC. | $96.11 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.90 | 2021 | |
| Amgen INC. | $53.60 | 2019-2025 | Krystexxa |
| Kowa Pharmaceuticals America, INC. | $34.12 | 2022 | |
| Glaxosmithkline, LLC. | $33.80 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $25.72 | 2020-2024 | Breztri |
| Scynexis, INC. | $17.57 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.48 | 2023 | Xifaxan |
| Eisai INC. | $16.44 | 2020 | |
| Ironwood Pharmaceuticals, INC | $16.31 | 2022 | |
| Seqirus USA INC | $14.42 | 2022 | |
| Sanofi Pasteur INC. | $12.12 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.70 | 2021 | |
| Merck Sharp & Dohme LLC | $11.29 | 2020 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.